Objective To assess the activity and safety of sequential lutetium-177 (177Lu)-PSMA-617 docetaxel vs on a background androgen deprivation therapy (ADT) in men with de novo metastatic hormone-naïve prostate cancer (mHNPC). Patients Methods UpFrontPSMA (NCT04343885) is an open-label, randomized, multicentre, phase 2 trial, recruiting 140 patients at 12 Australian centres. Key eligibility criteria...

Objective(s):Lutetium-177 can be made with high specific activity and with no other isotopes of lutetium present, referred to as “No Carrier Added” (NCA) 177Lu. We have radiolabelled DOTA-conjugated peptide DOTA‐(Tyr3)‐octreotate with NCA 177Lu (“NCA-LuTATE”) and used it in nearly 40 therapeutic administrations for subjects with neuroendocrine tumours or meningiomas. In this paper, we report on...

Background Leptomeningeal metastasis (LM) from solid tumors may be diagnosed in approximately 10% of patients with metastatic cancer and can occur virtually all malignant tumors. Median overall survival (OS) is poor limited to a few months LM-directed treatment, including available targeted therapy, immunotherapy radiation therapy. Omburtamab specifically binds B7-H3 (CD276), transmembrane glyc...

[177Lu]Lu-PSMA-617 (177Lu-PSMA-617) delivers β-particle radiation to prostate-specific membrane antigen (PSMA) expressing cells and the surrounding microenvironment. In phase III VISION study (NCT03511664), 177Lu-PSMA-617 + protocol-permitted standard of care (SOC) prolonged radiographic progression-free survival (rPFS; HR, 0.40; 99.2% CI: 0.29, 0.57), overall (OS; 0.62; 95% 0.52, 0.74) time fi...

Radioimmunotherapy (RIT) is a systemic therapy currently used in the treatment of patients with lymphoma. RIT complexes consist targeting molecule, commonly an antibody, radionuclide chelates and linker which can be nanoparticle platform. Nanoparticles facilitate attachment multiple radionuclides groups to single complex. Here target affinity, duration association inhibition colony formation Ce...

introduction one of the important applications of nuclear physics in medicine is the use of radioactive elements as radiopharmaceuticals. metastatic bone disease is the most common form of malignant bone tumors. samarium-153-ethylene diamine tetramethylene phosphonate (153sm-edtmp) as a radiopharmaceutical is used for pain palliation. this radiopharmaceutical usually emits beta particles, which...

Metastatic disease to bone is commonly seen in the advanced stages of many cancers. The cardinal symptom, pain, is often the cause of significant morbidity and reduced quality of life. Treatment of bone pain includes nonsteroidal analgesics and opiates; however, long-term use of these drugs is commonly associated with significant side effects, and tolerance is common. External-beam radiation th...

Pain is the commonest clinical manifestation of bone metastases. Its treatment is palliative in nature, and consists of chemotherapy, radiotherapy, hormonotherapy, diphosphonates, and drug therapy (i. e., opiates). Radioactive isotopes represent an appealing alternative to conventional treatment modalities. Among the different types of isotopes, wide clinical experience with Sm has been obtaine...

BACKGROUND Radiolabelled bombesin (BN) conjugates are promising radiotracers for imaging and therapy of breast and prostate tumours, in which BN2/gastrin-releasing peptide receptors are overexpressed. We describe the influence of the specific activity of a 177Lu-DOTA-PEG5k-Lys-B analogue on its therapeutic efficacy and compare it with its non-PEGylated counterpart. METHODS Derivatisation of a...

introduction: involvement of the skeleton can cause an excruciating pain in two-thirds of terminal patients with a history of malignancy. due to several limitations of other therapies, such as analgesics, bisphosphonates, chemotherapy, hormonal therapy and external beam radiotherapy; bone-seeking radiopharmaceuticals have an important role in palliation of pain from bone metastases. although th...